Affinity Bio Partners CEO Christina DiArcangelo Puller announced that she is adding another organization to the Affinity family of organizations by launching Affinity BioCeuticals, a "first of its kind" Cannabis Biotech Pennsylvania corporation. Affinity BioCeuticals is a Neutraceutical company focused on research and development of cannabinoid based therapies. The emergence of more and more indications where cannabinoid based treatment may be impactful to patient’s lives will be the primary focus for Affinity BioCeuticals.
“As we have seen through numerous studies that Affinity Bio Partners has had exposure to, cannabis and cannabis-based products can be very effective in treating a broad range of therapeutic areas. The Medical Cannabis market is emerging and it is time that Clinical Trial Protocols are developed in order to maximize efficacy and safety in patients that fall into these therapeutic areas,” said CEO, Christina DiArcangelo Puller. “Our goal is to ensure that Medical Cannabis is being utilized in the correct manner, while additionally ensuring that safe dosing protocols are being considered in the delivery methods. It is our organization's intent that through the utilization of Affinity Bio Partners’ CRO Services (clinical operations, safety, data management, regulatory services) we will achieve clinical trial results in a more efficient and rapid manner. This in turn will provide much needed relief to the many ill patients that are in desperate need of relief. As the CEO of each of the Affinity organizations, it is important to me that we always focus on helping provide assistance to unmet treatment needs for patients.”
Affinity BioCeuticals initially intends to focus its efforts on:
• Opioid abuse
• Oncology supportive care
Affinity BioCeuticals is led by a highly qualified team of executives with decades of biopharmaceutical, healthcare experience and significant background in drug development.